Drug intelligence / Profile preview

MK-0887G

Development stage: Unknown
Lead developer: Merck
Modality: Small Molecules
Administration: Topical

Overview

MK-0887G is an investigational topical cream formulation of mometasone furoate, a synthetic corticosteroid developed by Merck Sharp and Dohme (a subsidiary of Merck & Co.). Mometasone furoate acts as a glucocorticoid receptor agonist, providing anti-inflammatory, antipruritic, and vasoconstrictive activity. MK-0887G was developed for the treatment of infected dermatoses and has been studied in Phase 1 clinical trials involving healthy volunteers to characterize its dose-duration response and skin-blanching (vasoconstrictive) profile in comparison to the reference product, Elocon.

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on MK-0887G.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-0887G.

Explore the full profile